Commonwealth of Pennsylvania Public School Empls Retrmt SYS Acquires 1,161 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 8.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,375 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,161 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Supernus Pharmaceuticals were worth $453,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in Supernus Pharmaceuticals in the first quarter valued at approximately $41,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Supernus Pharmaceuticals in the 1st quarter worth $46,000. GAMMA Investing LLC raised its position in shares of Supernus Pharmaceuticals by 116.7% during the 2nd quarter. GAMMA Investing LLC now owns 2,861 shares of the specialty pharmaceutical company’s stock valued at $90,000 after buying an additional 1,541 shares in the last quarter. CWM LLC raised its position in shares of Supernus Pharmaceuticals by 92.4% during the 2nd quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock valued at $97,000 after buying an additional 1,479 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth $103,000.

Insiders Place Their Bets

In other news, SVP Frank Mottola sold 5,000 shares of the company’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $45.87, for a total transaction of $229,350.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares of the company’s stock, valued at approximately $710,801.52. This represents a 24.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Jack A. Khattar sold 59,900 shares of the stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the sale, the chief executive officer owned 1,206,578 shares of the company’s stock, valued at approximately $61,016,649.46. This represents a 4.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 183,135 shares of company stock valued at $8,773,587 over the last quarter. 8.80% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Piper Sandler raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the company from $40.00 to $65.00 in a research note on Thursday, October 9th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Tuesday. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 17th. Cantor Fitzgerald upped their target price on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 30th. Finally, Bank of America initiated coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They set a “buy” rating and a $65.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $63.25.

Supernus Pharmaceuticals Trading Up 0.4%

NASDAQ SUPN opened at $46.26 on Thursday. The firm has a market cap of $2.65 billion, a PE ratio of 40.23 and a beta of 0.75. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $57.65. The stock has a 50-day moving average of $48.59 and a 200-day moving average of $40.73.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). Supernus Pharmaceuticals had a return on equity of 14.22% and a net margin of 9.70%.The company had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $175.82 million. During the same period last year, the firm earned $0.69 earnings per share. Supernus Pharmaceuticals’s revenue for the quarter was up 9.3% on a year-over-year basis. Supernus Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.